Literature DB >> 20678586

Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate.

Naohiro Ohtaki1, Hidehiro Takahashi, Keiko Kaneko, Yasuyuki Gomi, Toyokazu Ishikawa, Yasushi Higashi, Takeshi Kurata, Tetsutaro Sata, Asato Kojima.   

Abstract

Virus-like particles (VLPs) of flaviviruses generated from the prM and E genes are a promising vaccine candidate. We have established cell clones continuously releasing VLPs of West Nile virus (WNV) in serum-free conditions. Two types of VLPs were distinguished by sedimenting analyses in sucrose density gradients. Fast sedimenting VLPs (F-VLPs) were large (40-50 nm) and composed of the E and processed mature M proteins, whereas slowly sedimenting VLPs (S-VLPs) were small (20-30 nm) particles consisting of the E and immature prM proteins. F-VLPs induced higher neutralizing antibody and anti-WNV IgG titers than S-VLPs. Furthermore, IgG2a was dominant over IgG1 by immunization with F-VLPs as with whole virion-derived antigens. Mice vaccinated with a low dose (3 ng) of F-VLPs showed higher protective efficacy (83% survivals) against WNV infection than S-VLP-immune mice (17% survivals). These results indicate that F-VLPs more closely resemble the virions and take a better immunogenic form than S-VLPs as WNV vaccine candidates.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20678586     DOI: 10.1016/j.vaccine.2010.07.055

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.

Authors:  Akane Urakami; Mya Myat Ngwe Tun; Meng Ling Moi; Atsuko Sakurai; Momoko Ishikawa; Sachiko Kuno; Ryuji Ueno; Kouichi Morita; Wataru Akahata
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

Review 2.  Plant-made vaccines against West Nile virus are potent, safe, and economically feasible.

Authors:  Qiang Chen
Journal:  Biotechnol J       Date:  2015-02-09       Impact factor: 4.677

3.  Zika virus-like particle vaccine fusion loop mutation increases production yield but fails to protect AG129 mice against Zika virus challenge.

Authors:  Danielle Thompson; Ben Guenther; Darly Manayani; Jason Mendy; Jonathan Smith; Diego A Espinosa; Eva Harris; Jeff Alexander; Lo Vang; Christopher S Morello
Journal:  PLoS Negl Trop Dis       Date:  2022-07-06

4.  Characterization of the ectodomain of the envelope protein of dengue virus type 4: expression, membrane association, secretion and particle formation in the absence of precursor membrane protein.

Authors:  Szu-Chia Hsieh; Wen-Yang Tsai; Vivek R Nerurkar; Wei-Kung Wang
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

5.  Zika virus like particles elicit protective antibodies in mice.

Authors:  Mauricio A Salvo; Brock Kingstad-Bakke; Cristhian Salas-Quinchucua; Erwin Camacho; Jorge E Osorio
Journal:  PLoS Negl Trop Dis       Date:  2018-02-05

6.  Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III.

Authors:  Yi-Chin Fan; Hsien-Chung Chiu; Li-Kuang Chen; Gwong-Jen J Chang; Shyan-Song Chiou
Journal:  PLoS Negl Trop Dis       Date:  2015-10-23

7.  Protection of a single dose west nile virus recombinant subviral particle vaccine against lineage 1 or 2 strains and analysis of the cross-reactivity with Usutu virus.

Authors:  Teresa Merino-Ramos; Ana-Belén Blázquez; Estela Escribano-Romero; Rodrigo Cañas-Arranz; Francisco Sobrino; Juan-Carlos Saiz; Miguel A Martín-Acebes
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

8.  Recognition of heparan sulfate by clinical strains of dengue virus serotype 1 using recombinant subviral particles.

Authors:  Charlermchai Artpradit; Luke N Robinson; Boris K Gavrilov; Troy T Rurak; Mathuros Ruchirawat; Ram Sasisekharan
Journal:  Virus Res       Date:  2013-05-22       Impact factor: 3.303

9.  Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus.

Authors:  Ryohei Saga; Akira Fujimoto; Noriyuki Watanabe; Mami Matsuda; Makoto Hasegawa; Koichi Watashi; Hideki Aizaki; Noriko Nakamura; Shigeru Tajima; Tomohiko Takasaki; Eiji Konishi; Takanobu Kato; Michinori Kohara; Haruko Takeyama; Takaji Wakita; Ryosuke Suzuki
Journal:  Sci Rep       Date:  2016-06-27       Impact factor: 4.379

10.  Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody.

Authors:  Wen-Fan Shen; Jedhan Ucat Galula; Jyung-Hurng Liu; Mei-Ying Liao; Day-Yu Chao; Cheng-Hao Huang; Yu-Chun Wang; Han-Chung Wu; Jian-Jong Liang; Yi-Ling Lin; Matthew T Whitney; Gwong-Jen J Chang; Sheng-Ren Chen; Shang-Rung Wu
Journal:  Elife       Date:  2018-10-18       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.